State of Alaska Department of Revenue Sells 1,026 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

State of Alaska Department of Revenue lowered its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,280 shares of the company’s stock after selling 1,026 shares during the period. State of Alaska Department of Revenue’s holdings in Prestige Consumer Healthcare were worth $2,038,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PBH. Opal Wealth Advisors LLC bought a new position in Prestige Consumer Healthcare in the second quarter worth $26,000. Quest Partners LLC increased its stake in shares of Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after acquiring an additional 424 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Prestige Consumer Healthcare by 80.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock valued at $33,000 after acquiring an additional 208 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after acquiring an additional 433 shares during the period. Finally, Gladius Capital Management LP bought a new stake in Prestige Consumer Healthcare during the second quarter worth about $35,000. Institutional investors own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on PBH shares. DA Davidson lifted their target price on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and an average price target of $94.20.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $74.05 on Friday. The company has a market cap of $3.67 billion, a price-to-earnings ratio of 18.11, a P/E/G ratio of 2.08 and a beta of 0.47. The business’s fifty day simple moving average is $72.17 and its two-hundred day simple moving average is $69.56. Prestige Consumer Healthcare Inc. has a 12 month low of $56.61 and a 12 month high of $75.80. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The company had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. During the same period last year, the company earned $1.06 EPS. Prestige Consumer Healthcare’s revenue for the quarter was down 4.4% on a year-over-year basis. Research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.43 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.